Newsbenzinga
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
· Published
Article summary
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
An excerpt from the original article.
Comments —
Loading comments…